In Vitro Activities of a New Des-Fluoro(6) Quinolone, Garenoxacin, against Clinical Anaerobic Bacteria

Liebetrau, A.; Rodloff, Arne C.; Behra-Miellet, Josette; Dubreuil, L.

doi:10.1128/aac.47.11.3667-3671.2003

Cited by 44 publications

(21 citation statements)

References 28 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biochemical properties and antibiotic susceptibilities of the isolates concurred well with previous publications (3,5,6,7,10). E. lenta and D. desulfuricans are mostly mentioned in relation to diseases in the gastrointestinal tract and the hepatobiliary tract.…”

supporting

confidence: 89%

Polymicrobial Bloodstream Infection with Eggerthella lenta and Desulfovibrio desulfuricans

et al. 2010

View full text Add to dashboard Cite

The advancement in culture identification methods has made possible the culture and identification of slow-growing anaerobic bacteria in clinical samples. Here, we describe a case of polymicrobial bloodstream infection (BSI) caused by Eggerthella lenta and Desulfovibrio desulfuricans, identified by API 20A and Vitek 2 systems and by 16S rRNA sequencing. CASE REPORTThe patient was an 86-year-old woman, living alone though provided with community home care assistance. In spring of 2009, the patient was admitted to hospital twice. The first time, she presented with dyspnea, an obstructive breathing pattern, confusion, and a high fever. She was admitted to a geriatric hospital where she stayed for 2 weeks and was initially treated with trimethoprim-sulfamethoxazole. Treatment was switched to cefuroxime after 3 days due to treatment failure, and the course was finished with amoxicillin. One week after getting discharged from the geriatric hospital, she was admitted to Stockholm South General Hospital. She presented with a fever, dyspnea, and this time with diarrhea as well. Upon examination, a decubital wound, not described earlier, which was 4 by 3 cm wide and 1 cm deep, was found in the sacrum area. She had a temperature of 39.3°C, a heart rate of 104 beats/minute, a blood pressure of 106/54 mm Hg, and a breathing frequency of 35 breaths/minute. Her white cell count at admission was 20 ϫ 10 9 /liter, and her C-reactive protein level was 104 mg/liter. Initially, the clinical picture together with the laboratory results was interpreted as a bloodstream infection (BSI) derived from an airway infection. However, the wound found in the sacrum, which appeared infected, was considered an alternative source for the infection. Cultures were taken from the blood, the nasopharynx, and the decubital wound. Growth was reported to occur in one blood culture vial on day 3. The nasopharynx culture showed no pathogenic bacteria, and the wound culture showed mixed bacterial flora containing several different types of Enterobacteriaceae. The antibiotic treatment was started with cefuroxime and then switched to amoxicillin after 2 days. The patient was discharged when both the clinical and the laboratory parameters, including C-reactive protein level and white cell count, were normalized after antibiotic treatment.Blood samples were cultured in a BacT/Alert 3D (bioMérieux, Inc., Durham, NC) automated blood culture system. After 52 h of incubation, one of two anaerobic blood culture vials signaled positive. Gram staining revealed Gram-positive bacilli. Broth from the anaerobic bottle was subcultured onto blood agar plates incubated in air, chocolate agar plates were incubated in 5% CO 2 , and blood agar plates were incubated in an anaerobic jar. After 48 h of incubation at 37°C, no growth was seen on the plates incubated in air and in those incubated in CO 2 . A tiny growth was seen in the plates incubated in the anaerobic jar, which was inhibited by a metronidazole disc (Oxoid, Ltd., Basingstoke, Hampshire, United Kingdom). The plate ...

show abstract

supporting

confidence: 89%

Polymicrobial Bloodstream Infection with Eggerthella lenta and Desulfovibrio desulfuricans

et al. 2010

View full text Add to dashboard Cite

show abstract

“…There are many documented instances of drug-resistant cases of BV developing after treatment with the regularly prescribed antibiotics (7,20,22), indicating the need for new treatment options. Considering the multitude of health risks associated with BV, ideally, there would be a low possibility of BV-associated organisms developing resistance to these new alternatives.…”

Section: Discussionmentioning

confidence: 99%

“…While effective, these broad-spectrum drugs do not effectively inhibit BV-associated pathogens. Subsequently, there is a high BV recurrence rate of ϳ20% (43), which is often characterized by newly developed antibiotic resistances (7,20,22). Furthermore, the concentrations of drugs required to inhibit the healthy vaginal microbiota are up to hundreds-fold than the concentrations used to control BV-associated pathogens, often resulting in eradication of the healthy vaginal microbiota (3).…”

mentioning

confidence: 99%

The Natural Antimicrobial Peptide Subtilosin Acts Synergistically with Glycerol Monolaurate, Lauric Arginate, and ε-Poly- l -Lysine against Bacterial Vaginosis-Associated Pathogens but Not Human Lactobacilli

Noll

Prichard

Khaykin

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

bSubtilosin is a cyclical antimicrobial peptide produced by Bacillus amyloliquefaciens that has antimicrobial activity against the bacterial vaginosis-associated human pathogen Gardnerella vaginalis. The ability of subtilosin to inhibit G. vaginalis alone and in combination with the natural antimicrobial agents glycerol monolaurate (Lauricidin), lauric arginate, and -poly-L-lysine was tested using a checkerboard approach. Subtilosin was found to act synergistically with all of the chosen antimicrobials. These promising results indicate that lower concentrations of subtilosin in combination with other compounds could effectively be used to inhibit growth of the pathogen, thereby decreasing the risk of developed antimicrobial resistance. This is the first report on the effects of subtilosin combined with other natural antimicrobials against G. vaginalis.

show abstract

“…Moreover, these treatments play a significant role in the expansion of drug resistance in G. vaginalis and Prevotella spp. (5,19). The failure of conventional antibiotics in BV cure and eradication raises the question of alternative therapeutic tools.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Rifaximin Vaginal Tablets in Treatment of Bacterial Vaginosis: a Molecular Characterization of the Vaginal Microbiota

Cruciani

Brigidi

Calanni³

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

ABSTRACTBacterial vaginosis (BV) is a common vaginal disorder characterized by an alteration of the vaginal bacterial morphotypes, associated with sexually transmitted infections and adverse pregnancy outcomes. The purpose of the present study was to evaluate the impact of different doses of rifaximin vaginal tablets (100 mg/day for 5 days, 25 mg/day for 5 days, and 100 mg/day for 2 days) on the vaginal microbiota of 102 European patients with BV enrolled in a multicenter, double-blind, randomized, placebo-controlled study. An integrated molecular approach based on quantitative PCR (qPCR) and PCR-denaturing gradient gel electrophoresis (PCR-DGGE) was used to investigate the effects of vaginal tablets containing the antibiotic. An increase in members of the genusLactobacillusand a decrease in the BV-related bacterial groups after the antibiotic treatment were demonstrated by qPCR. PCR-DGGE profiles confirmed the capability of rifaximin to modulate the composition of the vaginal microbial communities and to reduce their complexity. This molecular analysis supported the clinical observation that rifaximin at 25 mg/day for 5 days represents an effective treatment to be used in future pivotal studies for the treatment of BV.

show abstract

In Vitro Activities of a New Des-Fluoro(6) Quinolone, Garenoxacin, against Clinical Anaerobic Bacteria

Cited by 44 publications

References 28 publications

Polymicrobial Bloodstream Infection with Eggerthella lenta and Desulfovibrio desulfuricans

Polymicrobial Bloodstream Infection with Eggerthella lenta and Desulfovibrio desulfuricans

The Natural Antimicrobial Peptide Subtilosin Acts Synergistically with Glycerol Monolaurate, Lauric Arginate, and ε-Poly- l -Lysine against Bacterial Vaginosis-Associated Pathogens but Not Human Lactobacilli

Efficacy of Rifaximin Vaginal Tablets in Treatment of Bacterial Vaginosis: a Molecular Characterization of the Vaginal Microbiota

Contact Info

Product

Resources

About